GleamWall
中文EN

MREO Mereo BioPharma Group plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1719714 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY35.2%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-76.6%
ROA-64.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets19.8%
Debt / equity0.00x
Current ratio5.22x
Interest coverage-440.64x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$500,000$0
R&D expense$17.77M$20.93M
SG&A expense$23.01M$26.43M
Operating income-$40.11M-$47.36M
Interest expense$255,000$1.37M
Pretax income-$41.88M-$43.25M
Income tax$0$0
Net income-$41.88M-$43.25M
EBITDA-$39.95M-$47.22M
EPS (basic)-0.05-0.06
EPS (diluted)-0.05-0.06
Weighted avg. shares (diluted)797.12M739.62M
Balance sheet
Cash & equivalents$40.99M$69.80M
Current assets$45.02M$74.76M
PP&E, net$137,000$257,000
Intangibles$516,000$643,000
Total assets$45.92M$76.39M
Current liabilities$4.30M$13.85M
Total liabilities$5.00M$15.42M
Shareholders' equity$40.92M$60.97M
Cash flow statement
Operating cash flow-$30.97M-$32.83M
Capital expenditure$20,000$0
Free cash flow-$30.99M-$32.83M
Investing cash flow-$20,000-$699,000
Financing cash flow$327,000$46.15M
Depreciation & amortization$157,000$143,000
Stock-based compensation$7.60M$7.39M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.